Fionnuala Quinlan-Bennett, a 32-year-old primary school teacher from West Sussex, died in June after being unable to access a cancer drug that her oncologist believed could have extended her life. Quinlan-Bennett had been living with metastatic HER2-low breast cancer for two years, with the disease spreading to her bones and liver. Despite being on her third line of treatment with chemotherapy, her condition continued to deteriorate.
The drug, Enhertu, has been approved and is available in Scotland and 26 other European countries, including Ireland and France. However, the National Institute for Health and Care Excellence (NICE) initially rejected funding for the drug in England, Wales, and Northern Ireland in 2024, citing concerns over its cost. Enhertu, produced by AstraZeneca and Daiichi Sankyo, costs approximately £100,000 annually per patient, depending on dosage.
Quinlan-Bennett publicly shared her situation in April through a video recorded in her parents' garden, highlighting the frustration of being denied access to a treatment available to patients elsewhere in the UK and Europe. Her husband, Nathan Bennett, described her death on June 11 as a profound loss not only to their family but also to her community, colleagues, and the children she taught at St Peter’s Catholic Primary School in East Grinstead.
The couple married four years earlier at the Friary Church in Crawley, where her funeral was held, attended by 450 people in person and more than 500 online. Bennett has since campaigned for the NHS to negotiate a deal to make Enhertu accessible to the estimated 1,000 patients in England who could benefit annually from the treatment.
Trial data show Enhertu can extend life expectancy by an average of 6.6 months compared with existing therapies, with some patients living significantly longer. Although not a cure, the drug offers meaningful additional time for patients with advanced cancer.
NICE has reopened talks with AstraZeneca, Daiichi Sankyo, and NHS England after revising the threshold for cost-effectiveness following a US-UK trade agreement announced in December 2025. Discussions have been ongoing for several weeks to reach a commercial arrangement that would enable NHS funding of the drug, which would include a substantial discount from the list price.
Claire Rowney, CEO of the Breast Cancer Now charity, called for swift resolution, noting that other countries have found the drug affordable and accessible. A NICE spokesperson expressed condolences to Quinlan-Bennett’s family and reiterated commitment to negotiating a deal.
Shortly before her passing, Quinlan-Bennett authored notes on her phone contemplating her diminishing time, including a message intended for after her death, reflecting on unfulfilled plans and the impact she hoped to have. Nathan Bennett described the emotional toll of losing not only his wife but also the future they had envisioned together.
As negotiations continue, advocates emphasize the broader implications of access to innovative treatments for patients facing life-limiting illnesses and the difficult balance between cost and clinical benefit in healthcare decision-making.